Where Will Cisco Stock Be In 1 Year?
Cisco Systems (NASDAQ: CSCO) rarely makes the front page of fintech…
Buy
52
TNXP Quote, Financials, Valuation and Earnings
Last price:
$42.73
Seasonality move
:
-19.21%
Day range:
$35.13 - $38.43
52-week range:
$6.76 - $130.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.48x
P/B ratio:
1.56x
Volume:
619.6K
Avg. volume:
866.8K
1-year change:
-36.3%
Market cap:
$281M
Revenue:
$10.1M
EPS (TTM):
-$1,963.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$2.6M | -$1.88 | 17.75% | -99.9% | $61.67 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$38.36 | $61.67 | $281M | -- | $0.00 | 0% | 10.48x |
|
ATNM
Actinium Pharmaceuticals
|
$1.58 | $5.00 | $49.3M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.40 | -- | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.42 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
-- | -1.879 | -- | 11.24x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.5M | -$15.1M | -114.25% | -121.16% | -622.93% | -$16.6M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or ATNM?
Actinium Pharmaceuticals has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of -11511.11%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About TNXP or ATNM?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 60.76%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 216.46%. Given that Actinium Pharmaceuticals has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Actinium Pharmaceuticals is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is TNXP or ATNM More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock TNXP or ATNM?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or ATNM?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 10.48x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding10.48x -- $2.4M -$16.8M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns TNXP or NBY?
NovaBay Pharmaceuticals has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of -49.65%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About TNXP or NBY?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 60.76%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.89%. Given that Tonix Pharmaceuticals Holding has higher upside potential than NovaBay Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is TNXP or NBY More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock TNXP or NBY?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NBY?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 10.48x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding10.48x -- $2.4M -$16.8M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns TNXP or NNVC?
Nanoviricides has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About TNXP or NNVC?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 60.76%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Nanoviricides has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Nanoviricides is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NNVCNanoviricides0 0 0 -
Is TNXP or NNVC More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock TNXP or NNVC?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NNVC?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Nanoviricides's net income of -$2.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 10.48x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding10.48x -- $2.4M -$16.8M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns TNXP or OGEN?
Oragenics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M OGENOragenics-- -$3.60 -- -
What do Analysts Say About TNXP or OGEN?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 60.76%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Oragenics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 OGENOragenics0 1 0 -
Is TNXP or OGEN More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock TNXP or OGEN?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or OGEN?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Oragenics's net income of -$2.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 10.48x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding10.48x -- $2.4M -$16.8M OGENOragenics0.45x -- -- -$2.2M
-
Which has Higher Returns TNXP or TOVX?
Theriva Biologics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About TNXP or TOVX?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 60.76%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1388.73%. Given that Theriva Biologics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Theriva Biologics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 TOVXTheriva Biologics1 1 0 -
Is TNXP or TOVX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock TNXP or TOVX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or TOVX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 10.48x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding10.48x -- $2.4M -$16.8M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did David Tepper Sell Meta Stock?
Throughout 2024, David Tepper of Appaloosa Holdings sold more than…
The Market Tell Hiding in Plain Sight
Markets broadcast clues every day, but most traders tune in…
Stock Ideas
Buy
68
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 55x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
79
RYTM alert for Jul 10
Rhythm Pharmaceuticals [RYTM] is down 0.18% over the past day.
Sell
48
BGL alert for Jul 10
Blue Gold [BGL] is down 10.83% over the past day.
Buy
82
VRNA alert for Jul 10
Verona Pharma PLC [VRNA] is up 0.18% over the past day.
